| September 2010 | ||||||
|---|---|---|---|---|---|---|
| S | M | T | W | T | F | S |
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | ||
Monthly Archives
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
October 2008
September 2008
August 2008
July 2008
June 2008
April 2008
Complete Archives
Most recent entries
SpectraScience Provides Corporate Update and Outlook
SpectraScience appoints Sheldon L. Miller Esq. to its Board of Directors
SpectraScience Receives Notification of Pending Issuance of Two Patents
SpectraScience Retains Quorum Consulting
SpectraScience to Exhibit at Digestive Disease Week in New Orleans
SpectraScience Has Second Unannounced Inspection by FDA
SpectraScience’s Jim Hitchin Featured in MDDI Magazine Article
Health Radio - Interview with CEO, Jim Hichin
Professor Andreas Stallmach Chooses WavSTAT(R) Optical Biopsy System for Early Cancer Detection
SpectraScience CEO Jim Hitchin Speaks to Blogtalkradio About Better Cancer Screening Diagnostics
SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record
SpectraScience Forms Advisory Board - Governor Tommy Thompson to be Chairman
SpectraScience Releases Shareholder Newsletter
SpectraScience Engages European Contract Research Organization to Manage Clinical Trials
SpectraScience Awarded Japanese Patent 4361683 for Its Optical Biopsy Forceps System
News
SpectraScience Receives Notification of Pending Issuance of Two Patents
May 12, 2010
SANDIEGO, CA-- SpectraScience, Inc. (OTC.BB:SCIE), a SanDiego-based medical device company, announced today that it has been notifiedthat two patents will be issued for its technology. Both patents are for an"optical biopsy system and methods for tissue diagnosis." The patentswill be issued by the Japanese Patent office and the European Patent office.
Thepatent describes using fluorescence spectroscopy to characterize tissue. Nativetissue fluorescence ("autofluorescence") without requiringfluorescence-enhancing agents is used to distinguish between normal tissue,hyperplastic tissue, adenomatous tissue, and adenocarcinomas. It also describesa system that provides endoscopic image enhancement for easy location of atissue site for optical biopsy tissue characterization. The system allows theuse of an integrated endoscopic diagnosis and treatment device for immediatediagnosis and treatment without interchanging equipment and relocating thetissue site. The system provides an adjunctive tool to histopathological tissueclassification or, alternatively, further treatment that is based on theoptical biopsy system diagnosis.
JimHitchin, SpectraScience CEO, stated, "We hold approximately 60 patentsworldwide that have been issued or are pending on its WavSTAT® Optical BiopsySystem and LUMA® Cervical Imaging Systems. These devices are used to assesstissue quickly to help determine if it is normal, pre-cancerous, or cancerous.The WavSTAT and LUMA Systems are approved by the FDA for detectingpre-cancerous and cancerous tissue in the colon and cervix, respectively. Anevaluation of the WavSTAT for detection of pre-cancers in the throat("Barrett's esophagus") is being tested."
Forward-Looking Statements
Thisnews release contains forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, and Section 21E of theSecurities Exchange Act of 1934, as amended. These forward-looking statementsinvolve risks and uncertainties that may cause SpectraScience's actual resultsto differ materially from results discussed in forward-looking statements.Readers are urged to carefully review and consider the various disclosures madeby SpectraScience in this news release, its most recent Form 10-K and inSpectraScience's other reports filed with the Securities and ExchangeCommission ("SEC") that attempt to advise interested parties of therisks and factors that may affect SpectraScience's business. Theseforward-looking statements are qualified in their entirety by the cautions andrisk factors filed by SpectraScience in its annual report on Form 10-K andother documents.
About SpectraScience, Inc.
SpectraScienceis a San Diego-based medical device company that designs, develops,manufactures and markets spectrophotometry systems capable of determiningwhether tissue is normal, pre-cancerous or cancerous without physicallyremoving tissue from the body. The WavSTAT Optical Biopsy System uses light tooptically scan tissue and provide the physician with an immediate analysis.With FDA approval for sale in the U.S. and the CE Mark for the European Union,the WavSTAT System is the first commercially available product thatincorporates this innovative technology for clinical use. The Company's LUMAimaging technology has received FDA approval for an optical non-invasive systemthat is proven to more effectively detect cervical cancer precursors thanconventional methods available in the market today.
Contact:
SpectraScience, Inc.
Jim Hitchin
Chief Executive Officer
(858) 847-0200 x201
Hayden Communications
Investor Relations
Todd Pitcher
(858)-518-1387